查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1268937

2023-2030 年口腔粘膜剂的全球市场

Global Oral Transmucosal Drugs Market - 2023-2030
出版日期: | 出版商: DataM Intelligence | 英文 195 Pages | 商品交期: 约2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

市场概览

全球口腔粘膜剂市场预计将出现有利可图的增长，到 2022 年将达到 150.52 亿美元，到 2030 年将达到 244.414 亿美元。 预计在预测期内（2023-2030 年），口腔粘膜市场的复合年增长率为 6.4%。

在全球范围内，慢性或非传染性疾病呈上升趋势，占所有死亡人数的 73%。 在印度，非传染性疾病造成了 44% 的伤残调整生命年损失和 53% 的死亡。 印度拥有世界六分之一以上的人口，其高度发达的社会经济和慢性非传染性疾病的流行病学趋势导致口服药物市场增长加快。

2019 年冠状病毒病 (COVID-19) 大流行大大增加了临终和姑息治疗对替代给药途径的需求，尤其是在社区环境中。 经粘膜途径包括鼻内、口腔、舌下和直肠。 这些途径可以自我给药或由家庭护理人员给药，并且是全身给药的非侵入性途径。 自身免疫性疾病病例上升、技术进步和市场开发等因素正在推动全球经口粘膜市场的增长。

市场动态

自身免疫性疾病和癌症发病率上升推动市场增长

例如，美国癌症协会每年都会估计美国的新癌症病例和死亡人数，并彙编有关基于人群的癌症发病率和结果的最新数据。 2022 年，美国将有 1,918,030 例新癌症病例和 609,360 例癌症死亡病例，其中肺癌是癌症的首要原因，每天约有 350 例死亡。我在这里。 因此，癌症的流行正在推动市场的增长。

透粘膜药物的技术问题

经粘膜给药优于口服和肠胃外剂型，因为它是非侵入性的，可以自行给药或由经过培训的护理人员给药。 要找到适合经粘膜给药的药物，重要的是要了解粘膜药物吸收的机制。 虽然鼻腔、口腔和直肠粘膜各有独特的形态和生理特征，但它们也有一些共同点。

COVID-19 影响分析

由于供应链中断、政府封锁、劳动力短缺和製造活动限制，COVID-19 大流行对口服药物市场产生了短期的负面影响。 与此同时，口服药物製造商正受益于冠状病毒的爆发，首过代谢降低，起效更快。 由于这些特性，口服药物可用于姑息治疗和临终关怀以快速缓解症状。 在 COVID-19 大流行期间，这是强制性的，因为在某些情况下，患者的健康状况往往会迅速恶化。

俄乌衝突分析

俄罗斯和乌克兰由于渗透率低且缺乏主要市场参与者，估计对全球经口粘膜剂市场的影响不大。 但预计原材料进出口的影响在预测期内对全球口腔粘膜市场影响不大。

人工智能影响分析

人工智能 (AI) 在社会的许多领域无处不在，尤其是在製药行业。 人工神经网络 (ANN)、信息技术和无线通信都在帮助开发智能药物输送系统，这些系统有可能克服传统疗法的缺点。 通过无线连接，用于受监管药物分配的设备变得更加通用。

内容

第 1 章研究方法和范围

  • 调查方法
  • 调查目的和范围

第 2 章定义和概述

第 3 章执行摘要

  • 按产品类型分类的摘要
  • 按指示摘录
  • 按给药途径分类的片段
  • 按分发渠道分类的摘要
  • 区域摘要

第四章市场动态

  • 影响因素
    • 司机
      • 自身免疫性疾病、呼吸系统疾病和癌症的发病率上升推动了市场增长
      • 药物治疗/增加药物治疗的使用
    • 约束因素
      • 与透粘膜药物相关的监管问题
    • 机会
      • 启动研发活动
    • 影响分析

第五章行业分析

  • 波特的五力分析
  • 供应链分析
  • 未满足的需求
  • 监管分析

第 6 章 COVID-19 分析

  • COVID-19 分析
    • 在 COVID-19 情景之前
    • 当前的 COVID-19 情景
    • COVID-19 后或未来情景
  • COVID-19 期间的价格动态
  • 供需范围
  • 大流行期间与市场相关的政府举措
  • 製造商的战略举措
  • 结论

第七章俄乌战争分析

第八章全球经济衰退分析

第9章人工智能的影响分析

第 10 章按产品类型

  • 药丸
  • 电影
  • 液体/喷雾
  • 其他

第11章适应症

  • 阿片成瘾
  • 神经系统疾病
  • 勃起功能障碍
  • 噁心和呕吐
  • 其他

第12章给药途径

  • 舌下粘膜
  • 颊粘膜
  • 其他

第 13 章分销渠道

  • 零售药房
  • 医院药房
  • 在线药店

第14章按地区

  • 北美
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 意大利
    • 西班牙
    • 其他欧洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 澳大利亚
    • 其他亚太地区
  • 中东和非洲

第15章竞争格局

  • 竞争场景
  • 市场份额分析
  • 併购分析

第十六章公司简介

  • 辉瑞公司
    • 公司简介
    • 产品组合和说明
    • 财务摘要
    • 主要发展
  • ZIM Laboratories Limited
  • Aquestive Therapeutics, Inc
  • IntelGenx Corp
  • Indivior PLC
  • C.L.Pharm Co., Ltd
  • Seoul Pharmaceuticals
  • Shilpa Therapeutics
  • Sunovion Pharmaceuticals, Inc
  • CURE Pharmaceutical.

第17章 附录

简介目录
Product Code: PH4314

Market Overview

The global oral transmucosal drugs market reached US$ 15,005.2 million in 2022 and is projected to witness lucrative growth by reaching up to US$ 24,441.4 million by 2030. The oral transmucosal drugs market is expected to exhibit a CAGR of 6.4% during the forecast period (2023-2030).

Globally, chronic or non-communicable diseases are on the rise and are responsible for 73% of all fatalities. Non-communicable illnesses are to blame for 44% of lost disability-adjusted life years and 53% of all fatalities in India. More than a sixth of the world's people reside in India, which has been experiencing significant socio-economic development and an epidemiological trend towards chronic non-communicable diseases led to the rise in the oral transmucosal drugs market growth.

The Coronavirus disease 2019 (COVID-19) pandemic has led to a surge in the need for alternative routes of administration of drugs for end-of-life and palliative care, particularly in community settings. Transmucosal routes include intranasal, buccal, sublingual and rectal. They are non-invasive routes for systemic drug delivery with the possibility of self-administration, or administration by family caregivers. The factors such as growing cases of autoimmune disorders, technological advancements, and oral drugs market developments are boosting the global oral transmucosal drugs market growth.

Market Dynamics

Increase in the incidence of autoimmune disorders and cancer to boost the market growth

For instance, each year, the American Cancer Society estimates the number of new cancer cases and deaths in the U.S., and compiles the most recent data on population-based cancer occurrence and outcomes. In 2022, 1,918,030 new cancer cases and 609,360 cancer deaths were projected to occur in the U.S., including approximately 350 deaths per day from lung cancer, the leading cause of cancer. Thus, the prevelance of cancer boost the market growth.

Technical challenges of transmucosal drug

Transmucosal drug delivery is preferable to oral and parenteral forms of administration since it is non-invasive and enables self-administration or administration by trained carers. Understanding the mechanism of mucosal drug absorption is crucial in order to find medications that are right for transmucosal administration. The intranasal, oral, and rectal mucosa each have particular morphological and physiological traits, but they also have several things in common.

COVID-19 Impact Analysis

Due to supply chain disruption, a government-imposed lockdown, manpower shortages, and limitations on manufacturing activities, the COVID-19 pandemic had a short-term detrimental effect on the market for oral transmucosal medications. Oral transmucosal medication producers, on the other hand, are profiting from coronavirus outbreaks by providing reduced first-pass metabolism with a quick onset of action. These qualities make oral transmucosal medications useful for palliative care and end-of-life care to provide quick symptom alleviation. Since some patients' health has a tendency to rapidly decline in some circumstances, it was essential during the COVID-19 pandemic.

Russia-Ukraine Conflict Analysis

The Russia-Ukraine is estimated to have a minimal impact on the global oral transmucosal drugs market, owing to the low prevalence and absence of key market players in this region. However, the impact of the import and export of raw materials is anticipated to have little influence over the global oral transmucosal drugs market over the forecast period.

Artificial Intelligence Impact Analysis

Artificial intelligence (AI) has become more prevalent in a number of societal fields, most notably the pharmaceutical industry. Artificial neural networks (ANNs), information technology, and wireless communication all play a role in the development of smart medication delivery systems that have the potential to overcome the drawbacks of traditional therapeutic approaches. Devices for regulated drug distribution are more versatile, thanks to wireless connections.

For more details on this report - Request for Sample

Segment Analysis

The global oral transmucosal drugs market is segmented based on product type, indication, route of administartion, distribution channel, and region.

The opioid dependence segment is estimated to hold a majority of the oral transmucosal drugs market share during the forecast period.

The opioid dependence indication holds about 39.6% of the total oral transmucosal drugs market. The growing cases of opioid overdose is driving the segment growth. For instance, according to the World Health Organization 2021, globally about 0.5 million deaths are caused because of drug abuse. Over 70% of these deaths are associated with opioids, accounting for over 30% of those drug overdose deaths.

Moreover, prescribing of opioids in the Canada and U.S. has caused high rates of unacceptable death rates, prescription opioid abuse, and an immense obligation to the affected communities.

Geographical Analysis

Europe is estimated to hold the second-largest share of the global oral transmucosal drugs market during the forecast period.

The Europe region holds the second largest share of the global oral transmucosal drugs market accounting for approximately 29%. The market in the Europe region is being driven by the rising demand for pain management and active regional market participants.

For instance, Aquestive Therapeutics, Inc., a pharmaceutical company that develops drugs to solve patients' problems with current standards of care and provide transformative products to improve their lives, announced in September 2022 that it entered a license and supply agreement for Libervant (diazepam) Buccal Film with Pharmanovia. This agreement will allow Pharmanovia to market Libervant (diazepam) Buccal Film in the European Union, the UK, and other countries.

Competitive Landscape

The major global players in the market include Pfizer Inc., ZIM Laboratories Limited, Aquestive Therapeutics, Inc, IntelGenx Corp, Indivior PLC, C.L.Pharm Co., Ltd, Seoul Pharmaceuticals, Shilpa Therapeutics, Sunovion Pharmaceuticals, Inc, and CURE Pharmaceutical, among others.

Why Purchase the Report?

  • To visualize the global oral transmucosal drugs market segmentation based on product, application, and region,as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of oral transmucosal drugs market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as Excel consisting of key products of all the major players.

The global oral transmucosal drugs market report would provide approximately 53 tables, 54figures, and 195 pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Product Type
  • 3.2. Snippet by Indication
  • 3.3. Snippet by Route of Administration
  • 3.4. Snippet by Distribution Channel
  • 3.5. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increase in incidence of autoimmune disorders, respiratory problems, and cancer to boost the market growth
      • 4.1.1.2. The increase in medication and pharmacological therapy usage
    • 4.1.2. Restraints
      • 4.1.2.1. Regulatory challenges for transmucosal drug
    • 4.1.3. Opportunity
      • 4.1.3.1. Increasing number of research and developments activities
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Unmet Needs
  • 5.4. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Before COVID-19 Scenario
    • 6.1.2. Present COVID-19 Scenario
    • 6.1.3. Post COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During the Pandemic
  • 6.5. Manufacturers' Strategic Initiatives
  • 6.6. Conclusion

7. Russia-Ukraine War Analysis

8. Global Recession Analysis

9. Artificial Intelligence Impact Analysis

10. By Product Type

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 10.1.2. Market Attractiveness Index, By Product Type
  • 10.2. Tablets
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 10.3. Films
  • 10.4. Liquids & Spray
  • 10.5. Others

11. By Indication

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
    • 11.1.2. Market Attractiveness Index, By Indication
  • 11.2. Opioid Dependence *
    • 11.2.1. Introduction
    • 11.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 11.3. Neurological Disorders
  • 11.4. Erectile Dysfunction
  • 11.5. Nausea and Vomiting
  • 11.6. Others

12. By Route of Administration

  • 12.1. Introduction
    • 12.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 12.1.2. Market Attractiveness Index, By Route of Administration
  • 12.2. Sublingual Mucosa *
    • 12.2.1. Introduction
    • 12.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 12.3. Buccal Mucosa
  • 12.4. Others

13. By Distribution Channel

  • 13.1. Introduction
    • 13.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 13.1.2. Market Attractiveness Index, By Distribution Channel
  • 13.2. Retail Pharmacies*
    • 13.2.1. Introduction
    • 13.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 13.3. Hospital Pharmacies
  • 13.4. Online Pharmacies

14. By Region

  • 14.1. Introduction
    • 14.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 14.1.2. Market Attractiveness Index, By Region
  • 14.2. North America
    • 14.2.1. Introduction
    • 14.2.2. Key Region-Specific Dynamics
    • 14.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 14.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
    • 14.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 14.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 14.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 14.2.7.1. The U.S.
      • 14.2.7.2. Canada
      • 14.2.7.3. Mexico
  • 14.3. Europe
    • 14.3.1. Introduction
    • 14.3.2. Key Region-Specific Dynamics
    • 14.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 14.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
    • 14.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 14.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 14.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 14.3.7.1. Germany
      • 14.3.7.2. The U.K.
      • 14.3.7.3. France
      • 14.3.7.4. Italy
      • 14.3.7.5. Spain
      • 14.3.7.6. Rest of Europe
  • 14.4. South America
    • 14.4.1. Introduction
    • 14.4.2. Key Region-Specific Dynamics
    • 14.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 14.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
    • 14.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 14.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 14.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 14.4.7.1. Brazil
      • 14.4.7.2. Argentina
      • 14.4.7.3. Rest of South America
  • 14.5. Asia-Pacific
    • 14.5.1. Introduction
    • 14.5.2. Key Region-Specific Dynamics
    • 14.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 14.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
    • 14.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 14.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 14.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 14.5.7.1. China
      • 14.5.7.2. India
      • 14.5.7.3. Japan
      • 14.5.7.4. Australia
      • 14.5.7.5. Rest of Asia-Pacific
  • 14.6. Middle East and Africa
    • 14.6.1. Introduction
    • 14.6.2. Key Region-Specific Dynamics
    • 14.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 14.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
    • 14.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 14.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

15. Competitive Landscape

  • 15.1. Competitive Scenario
  • 15.2. Market Share Analysis
  • 15.3. Mergers and Acquisitions Analysis

16. Company Profiles

  • 16.1. Pfizer Inc.*
    • 16.1.1. Company Overview
    • 16.1.2. Product Portfolio and Description
    • 16.1.3. Financial Overview
    • 16.1.4. Key Developments
  • 16.2. ZIM Laboratories Limited
  • 16.3. Aquestive Therapeutics, Inc
  • 16.4. IntelGenx Corp
  • 16.5. Indivior PLC
  • 16.6. C.L.Pharm Co., Ltd
  • 16.7. Seoul Pharmaceuticals
  • 16.8. Shilpa Therapeutics
  • 16.9. Sunovion Pharmaceuticals, Inc
  • 16.10. CURE Pharmaceutical.

LIST NOT EXHAUSTIVE

17. Appendix

  • 17.1. About Us and Services
  • 17.2. Contact Us